News coverage about Amgen (NASDAQ:AMGN) has trended somewhat positive recently, Accern reports. Accern scores the sentiment of media coverage by reviewing more than twenty million news and blog sources. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Amgen earned a media sentiment score of 0.16 on Accern’s scale. Accern also gave news stories about the medical research company an impact score of 47.0484030070029 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.
These are some of the news stories that may have impacted Accern Sentiment’s scoring:
- Regeneron CEO: We’re trying to change the paradigm on dru… (finance.yahoo.com)
- Amgen Inc. (AMGN) – Lookout Watch Unusual Volume stock – Wall Street Morning (wallstreetmorning.com)
- Short Interest in Amgen, Inc. (AMGN) Increases By 20.2% (americanbankingnews.com)
- The ODYSSEY Trial Ends Well — But Will It Be Enough? (finance.yahoo.com)
- Regeneron and Sanofi Plan to Cut Cholesterol Drug Price (finance.yahoo.com)
Shares of Amgen (NASDAQ:AMGN) traded down $1.80 during trading hours on Monday, hitting $189.30. The stock had a trading volume of 6,970,000 shares, compared to its average volume of 6,690,000. Amgen has a twelve month low of $152.16 and a twelve month high of $201.23. The stock has a market cap of $136,400.00, a P/E ratio of 17.21, a PEG ratio of 2.35 and a beta of 1.37. The company has a debt-to-equity ratio of 1.35, a current ratio of 5.49 and a quick ratio of 5.17.
The business also recently declared a quarterly dividend, which will be paid on Friday, June 8th. Stockholders of record on Thursday, May 17th will be issued a $1.32 dividend. The ex-dividend date is Wednesday, May 16th. This represents a $5.28 dividend on an annualized basis and a dividend yield of 2.79%. Amgen’s dividend payout ratio is presently 48.00%.
Amgen declared that its Board of Directors has initiated a share buyback plan on Thursday, February 1st that authorizes the company to repurchase $10.00 billion in outstanding shares. This repurchase authorization authorizes the medical research company to repurchase shares of its stock through open market purchases. Stock repurchase plans are generally a sign that the company’s management believes its stock is undervalued.
Several equities research analysts have recently weighed in on AMGN shares. Vetr downgraded Amgen from a “buy” rating to a “hold” rating and set a $184.25 price target on the stock. in a report on Wednesday, January 3rd. Royal Bank of Canada reiterated a “hold” rating and issued a $189.00 price target on shares of Amgen in a report on Wednesday, January 24th. Piper Jaffray Companies reiterated a “buy” rating on shares of Amgen in a report on Tuesday, January 2nd. Cann reiterated a “buy” rating and issued a $205.00 price target on shares of Amgen in a report on Thursday, November 30th. Finally, Cowen reiterated a “buy” rating and issued a $204.00 price target on shares of Amgen in a report on Friday, February 2nd. One research analyst has rated the stock with a sell rating, fifteen have given a hold rating and eleven have given a buy rating to the stock. The company currently has an average rating of “Hold” and an average price target of $191.72.
In other news, EVP Sean E. Harper sold 1,525 shares of Amgen stock in a transaction on Tuesday, December 12th. The stock was sold at an average price of $176.83, for a total value of $269,665.75. Following the transaction, the executive vice president now directly owns 56,106 shares in the company, valued at approximately $9,921,223.98. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Insiders sold a total of 4,575 shares of company stock worth $818,361 over the last quarter. Company insiders own 0.19% of the company’s stock.
Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine).
Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.